A novel treatment of diaper dermatitis in children and adults.
barrier cream
diaper dermatitis
topical treatments
Journal
Journal of cosmetic dermatology
ISSN: 1473-2165
Titre abrégé: J Cosmet Dermatol
Pays: England
ID NLM: 101130964
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
accepted:
16
03
2021
entrez:
2
5
2021
pubmed:
3
5
2021
medline:
15
5
2021
Statut:
ppublish
Résumé
Diaper dermatitis (DD) is an acute inflammatory reaction, regardless of the cause, of the diaper-covered area. Topical skin barrier repair cosmetic products are the mainstay treatment to cure and/or prevent DD. To assess the efficacy/tolerability of a zinc gluconate-taurine/zinc oxide and panthenol/ glycerin/ Butyrospermum parkii butter barrier cream using clinical evaluation. In this prospective, open-label trial, 20 patients (10 infants/10 adults), with mild/moderate DD enrolled at the Dermatology University Clinic of Catania (Italy) were instructed to apply the cream twice daily for 30 days. Degree of erythema was performed clinically by a 5-point severity scale (from 0 = no erythema to 4 = severe erythema), at baseline, at 15 and 30 days. An Investigator Global Assessment (IGA) using a 6-point scale (from -1 = worsening to 4 = complete response/clear) along with product tolerability was also performed at 15 and 30 days. Statistical analysis was performed using SAS version 9. At 15 days, a reduction of clinical erythema assessment (CEA) from baseline was observed (mean from 3.2 ± 0.8 to 2.5 ± 0.3; p < 0.06), that although nonsignificant, showed a significant progressive improvement at 30 days (mean from 3.2 ± 0.8 to 1.1 ± 0.9; p < 0.0001) without any age differences. Our preliminary results indicate that the tested barrier cream may represent a promising approach in DD rash. It may be used in mild-to-moderate forms in monotherapy without significant side effects or, where required, in association with pharmacological agents. Its long-term use is likely safe.
Sections du résumé
BACKGROUND
BACKGROUND
Diaper dermatitis (DD) is an acute inflammatory reaction, regardless of the cause, of the diaper-covered area. Topical skin barrier repair cosmetic products are the mainstay treatment to cure and/or prevent DD.
AIMS
OBJECTIVE
To assess the efficacy/tolerability of a zinc gluconate-taurine/zinc oxide and panthenol/ glycerin/ Butyrospermum parkii butter barrier cream using clinical evaluation.
METHODS
METHODS
In this prospective, open-label trial, 20 patients (10 infants/10 adults), with mild/moderate DD enrolled at the Dermatology University Clinic of Catania (Italy) were instructed to apply the cream twice daily for 30 days. Degree of erythema was performed clinically by a 5-point severity scale (from 0 = no erythema to 4 = severe erythema), at baseline, at 15 and 30 days. An Investigator Global Assessment (IGA) using a 6-point scale (from -1 = worsening to 4 = complete response/clear) along with product tolerability was also performed at 15 and 30 days. Statistical analysis was performed using SAS version 9.
RESULTS
RESULTS
At 15 days, a reduction of clinical erythema assessment (CEA) from baseline was observed (mean from 3.2 ± 0.8 to 2.5 ± 0.3; p < 0.06), that although nonsignificant, showed a significant progressive improvement at 30 days (mean from 3.2 ± 0.8 to 1.1 ± 0.9; p < 0.0001) without any age differences.
CONCLUSIONS
CONCLUSIONS
Our preliminary results indicate that the tested barrier cream may represent a promising approach in DD rash. It may be used in mild-to-moderate forms in monotherapy without significant side effects or, where required, in association with pharmacological agents. Its long-term use is likely safe.
Identifiants
pubmed: 33934478
doi: 10.1111/jocd.14091
pmc: PMC8252753
doi:
Substances chimiques
Emollients
0
Zinc Oxide
SOI2LOH54Z
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-4Informations de copyright
© 2021 The Authors. Journal of Cosmetic Dermatology published by Wiley Periodicals LLC.
Références
Clin Dermatol. 2015 Jul-Aug;33(4):477-82
pubmed: 26051065
Amino Acids. 2014 Jan;46(1):7-20
pubmed: 22810731
Nanomedicine. 2014 Aug;10(6):1195-208
pubmed: 24607937
J Cosmet Sci. 2011 Jul-Aug;62(4):361-70
pubmed: 21982351
Int J Dermatol. 2018 Mar;57(3):265-275
pubmed: 28986935
J Complement Integr Med. 2012 Jan 12;9:Article 4
pubmed: 22499721
Pediatr Dermatol. 2018 Mar;35 Suppl 1:s19-s23
pubmed: 29596731
Br J Dermatol. 2017 Nov;177(5):1256-1271
pubmed: 28432721
Dermatol Res Pract. 2014;2014:709152
pubmed: 25120566